S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

from OncLive® On Air · host OncLive® On Air

Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.

Episode metadata supplied by the publisher feed · Published Aug 21, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML

0:00 10:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 10 minutes long.

When was this OncLive® On Air episode published?

This episode was published on August 21, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!